Insider Selling: SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells 6,168 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Well Van sold 6,168 shares of the company’s stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $7.63, for a total transaction of $47,061.84. Following the completion of the transaction, the insider owned 338,884 shares in the company, valued at approximately $2,585,684.92. This trade represents a 1.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

SOPHiA GENETICS Price Performance

SOPHiA GENETICS stock traded down $0.01 during mid-day trading on Monday, hitting $7.86. 309,330 shares of the company traded hands, compared to its average volume of 261,716. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69. SOPHiA GENETICS SA has a one year low of $3.12 and a one year high of $8.98. The stock has a market cap of $659.38 million, a price-to-earnings ratio of -6.83 and a beta of 0.98. The stock has a fifty day moving average price of $7.03 and a 200-day moving average price of $5.69.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The company had revenue of $23.31 million for the quarter, compared to analysts’ expectations of $21.72 million. On average, equities analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on SOPH shares. Zacks Research upgraded SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research raised their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Finally, HC Wainwright boosted their price objective on shares of SOPHiA GENETICS from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $10.00.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of large investors have recently bought and sold shares of SOPH. Maven Securities LTD bought a new stake in SOPHiA GENETICS in the second quarter valued at approximately $866,000. AXQ Capital LP purchased a new stake in SOPHiA GENETICS during the 2nd quarter valued at $119,000. AWM Investment Company Inc. purchased a new position in shares of SOPHiA GENETICS in the second quarter valued at about $9,809,000. Hennion & Walsh Asset Management Inc. bought a new position in shares of SOPHiA GENETICS during the second quarter valued at about $567,000. Finally, Royal Bank of Canada raised its stake in shares of SOPHiA GENETICS by 3,130.2% during the first quarter. Royal Bank of Canada now owns 19,381 shares of the company’s stock valued at $96,000 after acquiring an additional 18,781 shares during the last quarter. 31.59% of the stock is owned by hedge funds and other institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS Ltd. is a healthcare technology company that develops data-driven medicine solutions for healthcare institutions, pharmaceutical companies and research organizations. The company’s platform is designed to help users analyze complex genomic and multimodal data and apply insights to clinical research and patient care.

Its core offering, the SOPHiA DDM platform, combines cloud-based software, artificial intelligence and machine-learning tools to support the interpretation of genomic data.